First versus second-generation molecular profiling tests: How both can guide decision-making in early-stage hormone-receptor positive breast cancers?

Researchers examined the advantages and limitations of the molecular profiling tests Oncotype DX and Prosigna. They concluded that more research comparing the two tests is needed to harness these tests’ potential and to refine treatment decisions. Additionally, pairing both tests could help to identify patients who would benefit from chemotherapy.